Performance analysis of DiaMedica Therapeutics (DMAC)
Annual Return
Over the past 3 years, DMAC has had an average annual return of +25.22%, outperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, DMAC has had an average annual return of +13.09%, outperforming the benchmark SPY, which returned +12.73% annual.
Over the past 10 years, DMAC has had an average annual return of +4.01%, underperforming the benchmark SPY, which returned +15.04% annual.
Since Jan 4, 2008, DMAC has had an average annual return of -6.76%, underperforming the benchmark SPY, which returned +11.42% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.03% | +46.60% | +91.22% | +79.77% | -57.66% | -63.22% | +109.11% | +66.70% | -41.82% | +127.81% | +15.60% | +89.87% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||
| -93.50% | -33.49% | -25.93% | +64.60% | +95.50% | -58.87% | -9.15% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.01% | -1.10% | -14.86% | -10.63% | -0.99% | +17.52% | +0.59% | -11.03% | |||||
| 2025 | +6.08% | +13.40% | -41.96% | +9.53% | -1.00% | -5.12% | +8.26% | +35.26% | +20.34% | +2.76% | +22.22% | -7.77% | +46.60% |
| 2024 | -0.64% | +6.35% | -7.71% | -8.63% | +14.58% | +1.79% | +11.18% | +19.79% | +6.61% | +4.28% | +29.43% | -4.00% | +91.22% |
| 2023 | -14.47% | +28.08% | -11.56% | +6.62% | +67.36% | +58.23% | -21.77% | -12.68% | -12.59% | -15.51% | +11.92% | +16.40% | +79.77% |
| 2022 | -30.57% | +1.50% | -4.94% | -7.17% | +4.70% | -16.79% | -18.38% | +7.24% | -29.96% | -4.82% | +0.88% | +32.75% | -57.66% |
| 2021 | -20.82% | +14.20% | -0.23% | +2.75% | -21.17% | -39.96% | -22.48% | +24.62% | -6.71% | -1.49% | -5.33% | -0.28% | -63.22% |
| 2020 | -10.18% | +3.76% | -38.05% | +41.09% | +16.96% | +49.97% | -14.13% | -20.17% | -10.77% | +3.55% | +27.57% | +81.08% | +109.11% |
| 2019 | +34.02% | -14.06% | +35.50% | -27.12% | -16.33% | +79.08% | -24.78% | -20.13% | -30.51% | +38.64% | +9.77% | +53.92% | +66.70% |
| 2018 | +7.17% | +2.18% | +25.47% | +20.76% | +5.39% | +23.98% | -15.50% | -14.83% | +7.63% | -21.57% | -28.09% | -38.56% | -41.82% |
| 2017 | +3.91% | +31.09% | +42.05% | +25.87% | -21.19% | -4.07% | +5.08% | -2.08% | +44.28% | -0.39% | -7.91% | -9.16% | +127.81% |
Drawdown analysis of DiaMedica Therapeutics (DMAC)
The maximum drawdown for the DMAC was -98.16%, occurring on Dec 5, 2014. This drawdown has not yet recovered.
The current DMAC drawdown is -83.97%.
Since Jan 4, 2008 DMAC has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 3 times
- 20% or more: 4 times
- 10% or more: 5 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.16% | Aug 7, 2012 | 586 | Dec 5, 2014 | Ongoing | Ongoing | Ongoing |
| -73.05% | Jan 4, 2008 | 365 | Jun 17, 2009 | 405 | Jan 25, 2011 | 770 |
| -36.88% | Mar 8, 2011 | 180 | Nov 21, 2011 | 65 | Feb 27, 2012 | 245 |
| -25.49% | Feb 28, 2012 | 57 | May 18, 2012 | 50 | Jul 31, 2012 | 107 |
| -16.15% | Jan 27, 2011 | 20 | Feb 25, 2011 | 7 | Mar 8, 2011 | 27 |